Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMD14 | O00487 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4934112 | 0.71 | CD38 (0.40) | — | |
| SCHEMBL14114414 | 0.71 | CD38 (0.40) | — | |
| SCHEMBL4931435 | 0.62 | ANO1 (0.40) | KMT2A | |
| SCHEMBL4934606 | 0.61 | CHRM2 (0.36) | ALDH1A1SMN1; SMN2HTTL3MBTL1 | |
| SCHEMBL4931441 | 0.61 | TBK1 (0.39) | ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL4933915 | 0.60 | TBK1 (0.41) | ALDH1A1 | |
| SCHEMBL5007705 | 0.57 | EPHX2 (0.31) | — | |
| SCHEMBL4930917 | 0.56 | ALDH1A1 (0.46) | ALDH1A1L3MBTL1 | |
| SCHEMBL4924406 | 0.55 | HSPA5 (0.40) | SMN1; SMN2KMT2A | |
| SCHEMBL13527534 | 0.54 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2GAAKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080167309-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS, LTD. (UK) | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167309-A1 | Pharmaceutical Compounds | CCNO, CDK2, CDK1 | PSMD14 3968/4885ALDH1A1 3464/4885SMN1; SMN2 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.